

## Some general insights in the scale up for a multigram synthesis under GMP of one oligosaccharide

Arthur BODENMUELLER [1], Laurence MULARD [3], Fiona LIN [2], Viliam PAVLIAK [2], Jan RADISSON [1], Manuel SCHERER [1], Patrick TROULLIEUX

[1] SynphaBase AG, Güterstrasse 82, CH-4133 Pratteln, Switzerland, [2] Bill & Melinda Gates Medical Research Institute, [3] Institute Pasteur, Paris, France [4] IC2D Consulting, France [4]

a.bodenmueller@synphabase.ch

Subject proposed will deal with the development and production work to produce an oligosaccharide planned to be conjugated to a protein. This final conjugated oligosaccharide is intended to be used to initiate preclinical and phase I/II clinical studies of a vaccine drug.

Presentation will focus on scale-up for a kg scale production of several synthesis intermediates as well as gram scale of last steps synthesis, which were done under GMP to deliver gram scale of this oligosaccharide. Emphasis will be done on how development was conducted to avoid problems or concerns during scale up, starting from medicinal chemistry lab procedures.